Document Detail


Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
MedLine Citation:
PMID:  22297008     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Although neuroendocrine tumors (NETs) have been recognized as a family of complex malignancies since 1907, major progress has been made only in the past 20 years in understanding and managing the disease. The detection and reported incidence of NETs have increased fivefold since 1973, suggesting that the tumors may be more common than previously believed. NETs arise predominantly in the gastrointestinal tract but can occur in any tissue containing endocrine precursor cells and can secrete hormone peptides that exert clinical symptoms of flushing and diarrhea. With the introduction of the somatostatin analog (SSA) octreotide in 1987, symptom management of NETs improved by diminishing morbidities and mortality associated with carcinoid syndrome. Clinical results suggest that the SSA agents octreotide and lanreotide also may provide antitumor benefits in addition to their suppression of carcinoid syndrome. Oncology nurses should be aware of the expanded role of SSA agents for symptom management and tumor control in patients with NETs and communicate treatment benefits, side-effect management, and effective adherence with patients for the optimal clinical management of NETs.
Authors:
Nancy M Gardner-Roehnelt
Related Documents :
20603598 - Pharicin a, a novel natural ent-kaurene diterpenoid, induces mitotic arrest and mitotic...
22404218 - Sulfasalazine for brain cancer fits.
16829208 - Endpoints for agents that slow tumor growth.
22528338 - Oblique approach for ct-guided liver radiofrequency ablation using multiplanar reformat...
8306348 - Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin ...
23135478 - Epithelial-mesenchymal transition-related gene expression as a new prognostic marker fo...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical journal of oncology nursing     Volume:  16     ISSN:  1538-067X     ISO Abbreviation:  Clin J Oncol Nurs     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9705336     Medline TA:  Clin J Oncol Nurs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  56-64     Citation Subset:  N    
Affiliation:
Neuroendocrine Tumor Division of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Survey of experiences of an e-mentorship program: Part II.
Next Document:  What men say about surviving prostate cancer: complexities represented in a decade of comments.